ExAdEx U.S. patent about core technology officially granted

The United States Patent and Trademark Office has granted a U.S. patent covering the ExAdEx core technology: a major milestone for our intellectual property portfolio and a confirmation of our science-driven approach.

A technology built to bridge the gap between preclinical research and human biology

At the core of ExAdEx-Innov’s platform is a fundamental challenge that the biomedical research community has long faced: the inability of traditional testing methods (2D cell cultures, animal models, or synthetic scaffolds) to accurately predict human outcomes. By working exclusively with donor-derived human adipose tissue, our patented ExAdEx technology generates fully functional 3D ex vivo models that preserve what makes human tissue unique: mature adult and progenitor cells, an intact vascular and lymphatic network, and a native three-dimensional extracellular matrix — with no exogenous materials added.

The result is a platform that delivers first-in-human data without a single patient enrolled in a trial.

What the ExAdEx platform enables

Because our models retain the biological complexity of real human tissue, they open the door to a broad range of research and testing applications across:

• pharmaceutical,
• dermo-cosmetic, and
• longevity science.

In pharmaceutical R&D, the platform is tailored to address metabolic diseases such as obesity, insulin resistance, and cardiometabolic conditions, as well as the tissue-level responses that accompany them: fibrosis, chronic inflammation, extracellular matrix remodeling, and vascular impairment. Our models support mechanism-of-action studies, biomarker identification, and early compound profiling, providing actionable data that helps teams make better-informed go/no-go decisions well before clinical development begins.

In dermo-cosmetics and aesthetic medicine, the same tissue architecture enables precise claims validation and active ingredient testing in a physiologically relevant context that no reconstructed model can replicate. From anti-aging strategies to the study of complex phenomena like GLP-1-induced tissue changes, ExAdEx models provide mechanistic insights directly translatable to human populations.

The platform also underlies the ExAdEx Longevity Lab™, our hybrid in silico / ex vivo framework designed to study aging and tissue rejuvenation through a holistic, multi-endpoint approach: exploring senescence, inflammaging, mitochondrial dysfunction, stem cell pool exhaustion, and vascular impairment in a single integrated system.

A strengthened IP position on a key market

This U.S. patent grant is a significant step for ExAdEx-Innov’s intellectual property strategy. The United States represents the world’s largest pharmaceutical and biotechnology market, and this protection reinforces our ability to operate and partner with confidence on that market, while confirming the value of years of scientific development carried out in collaboration with our academic founding partners CNRS, INSERM, Université Côte d’Azur, CHU de Nice, and supported by local and national agencies SATT Sud-Est, BpiFrance, Réseau Entreprendre Côte d’Azur, Metropole Nice Côte d’Azur and Incubateur Provence Côte d’Azur.

Follow us on LinkedIn and contact us for more information.